Moyamoya disease

Moyamoya disease (MS). It is a vasculopathy characterized by a progressive stenosis (until occlusion) of the terminal portion of both internal carotids, which may include the anterior (ACÁ) and middle cerebral arteries (ACM), associated with an abnormal vascular network of vessels called moyamoya. It is a rare disease in pediatrics .

Summary

[ hide ]

  • 1 Epidemiology
  • 2 Etiology
  • 3 Diagnosis
  • 4 Clinical manifestations
  • 5 Treatment
  • 6 Forecast
  • 7 Source

epidemiology

MS was described as such for the first time in Japan , where it is the leading cause of cerebrovascular disease in children, with an incidence of 3% per cent per year, unlike that described in Europe, which is ten times lower. Twice as often affects women . A bimodal age distribution is described, one group in the first decade of life, and a second group in adults between 30 and 40 years of age.

Etiology

It is unknown, although different studies have associated its pathogenesis with genetic and environmental factors. In Pediatrics it generally manifests as transient ischemic attacks or cerebral infarcts , while in adults cerebral hemorrhage is more frequent

Diagnosis

The certain diagnosis of MS is by digital angiography (AD). Nuclear magnetic resonance angiography (RNAM) can also be used as a useful diagnostic method.

Clinical manifestations

Four main types of clinical manifestations:

  • Symptoms due to subarachnoid hemorrhageor intracerebral hemorrhage
  • Cerebral infarction
  • Transient Cerebral Ischemic Attacks (TIA)
  • Seizuresor a combination of these symptoms

The heart attacks and seizures occur most often in children under 10 years; Between 20 and 40 years of age, the symptoms are usually due to cerebral hemorrhage .

Treatment

Regarding medical treatment , patients with Moyamoya are sometimes given antiplatelet agents, usually this is the therapy of choice when the disease is mild or the patient is at high surgical risk, but there are few data that demonstrate its efficacy in the short or long term. term. Blood thinners such as warfarin are rarely used in the treatment of children with Moyamoya, due to the difficulty in maintaining therapeutic blood levels and the risk of bleeding after minor trauma. They were used heparins of low molecular weight and also, channel antagonists of the calcium to try to treatheadache and prevent the frequency and severity of episodes of refractory transient cerebral ischemia. Surgical revascularization procedures are widely used in the treatment of Moyamoya disease, particularly in patients with cognitive impairment or with recurrent and progressive symptoms. The surgical anastomotic direct connection of the artery superficial temporal artery to middle cerebral, is often technically difficult to perform on children because of the small size of the vessels in the scalp and the middle cerebral artery receiver. Indirect revascularization procedures include encephaloduroarteriosinangiosis and encephalomyoarteriosinangiosis.

Forecast

The prognosis for Moyamoya disease is difficult to predict because its natural history is not firmly established. Between 50 and 66% of untreated patients with Moyamoya will experience severe neurological impairment compared to 2.6% impairment in children treated surgically.

 

Leave a Comment

Scroll to Top